{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"28.0","value":"13.50"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"22.0","value":"11.00"},{"groupId":"OG002","lowerLimit":"3.0","upperLimit":"21.0","value":"10.00"},{"groupId":"OG003","lowerLimit":"7.0","upperLimit":"25.0","value":"10.00"},{"groupId":"OG004","lowerLimit":"3.0","upperLimit":"23.0","value":"10.00"},{"groupId":"OG005","lowerLimit":"7.0","upperLimit":"28.0","value":"13.50"},{"groupId":"OG006","lowerLimit":"4.0","upperLimit":"22.0","value":"9.50"},{"groupId":"OG007","lowerLimit":"7.0","upperLimit":"21.0","value":"14.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"24"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"Tmax is the first study day the maximum observed concetration (Cmax) of JCARH125 CAR T cells in the blood is reached as determined by quantitative polymerase chain reaction (qPCR) to detect the JCARH125 transgene.","dispersionType":"Full Range","groups":[{"description":"JCARH125 IV at dose level 50 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 50 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 150 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG001","title":"Phase 1 150 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 300 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG002","title":"Phase 1 300 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 450 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG003","title":"Phase 1 450 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG004","title":"Phase 1 600 x 10^6 Cells"},{"description":"2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG005","title":"Phase 1 Anakinra 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG006","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG007","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"MEDIAN","populationDescription":"All participants who have the necessary PK measurements to provide interpretable results for this specific parameter of interest","reportingStatus":"POSTED","timeFrame":"From JCARH125 infusion through the day 29 visit","title":"Time to Maximum Observed Concentration (Tmax)","type":"SECONDARY","unitOfMeasure":"Day"}